BIW-8962 is a humanized anti-ganglioside GM2 antibody demonstrating ADCC/CDC activity against multiple myeloma cells. In murine xenograft models, BIW-8962 exhibits potent antitumor activity. This compound is applicable for research on cancers such as myeloma.

BIW-8962 (0.01-1 μg/mL) exhibits ADCC activity in GM2-expressing SBC-3 cells.

B BIW-8962 (0.1-10 mg/kg, administered intravenously every two weeks for 3-4 weeks) demonstrated anti-tumor activity in KMS-11 and OPM-2/GFP severe combined immunodeficiency (SCID) mouse models. In the SBC-3 SCID mouse model with natural killer cell depletion, BIW-8962 (0.1-10 μg/100μL, intravenously once daily on days 7, 14, 21, 28, and 35 post SBC-3 cell injection) effectively inhibited tumor metastasis across multiple organs, increased the number of apoptotic cells, and extended survival duration.